clinical trial · NCT06029439
Study to Assess the Safety and Effectiveness of NMRA-335140-501
Major Depressive DisorderNMRA-335140
brief summary
This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy and safety of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), and complete the 6 weeks double-blind treatment, provide informed consent, and meet eligibility criteria, may enter this extension study.
started
Nov 10, 2023
primary completion
Jun 1, 2027
completion
Jun 1, 2027
last updated
Apr 8, 2026
official title
Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants With Major Depressive Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol